Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 11/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 3/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14813112 | 0.92 | DGAT1 (0.50) | DGAT1NPSR1L3MBTL1KMT2AJAK2 | |
| SCHEMBL4937714 | 0.79 | DGAT1 (0.52) | DGAT1L3MBTL1JAK2JAK1TYK2 | |
| SCHEMBL4937718 | 0.79 | DGAT1 (0.52) | DGAT1L3MBTL1JAK2JAK1TYK2 | |
| SCHEMBL27769397 | 0.78 | DGAT1 (0.44) | DGAT1JAK2JAK1TYK2JAK3 | |
| SCHEMBL27790808 | 0.77 | DGAT1 (0.43) | DGAT1JAK2JAK1TYK2JAK3 | |
| SCHEMBL4470890 | 0.77 | DGAT1 (0.52) | DGAT1JAK2JAK1TYK2JAK3 | |
| SCHEMBL11887698 | 0.77 | KMT2A (0.60) | NPSR1L3MBTL1KMT2APOLBTP53 | |
| SCHEMBL180761 | 0.77 | DGAT1 (0.49) | DGAT1KMT2AJAK2JAK1TYK2 | |
| SCHEMBL71634 | 0.76 | KMT2A (0.59) | NPSR1L3MBTL1KMT2APOLBTP53 | |
| SCHEMBL27769423 | 0.76 | DGAT1 (0.51) | DGAT1L3MBTL1JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2117526-B1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LAB (US) | 2013-04-03 | — | — | EP | claimed |
| US-20120238581-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBVIE INC. | 2012-09-20 | — | — | US | claimed |
| EP-2117526-A2 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | Abbott Laboratories (US) | 2009-11-18 | — | — | EP | claimed |
| US-20080182861-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBVIE INC. | 2008-07-31 | — | — | US | claimed |
| WO-2008067257-A2 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2008-06-05 | — | — | WO | claimed |
| US-8586594-B2 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBVIE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2117526-B1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LAB (US) | 2013-04-03 | — | — | EP | disclosed |
| US-20120238581-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBVIE INC. | 2012-09-20 | — | — | US | disclosed |
| US-8202878-B2 | Type 2 diabetes, obesity, elevated plasma triglycerides, metabolic syndrome, non-alcoholic steatohepatitis, and non-alcoholic fatty liver disease;Trans [4-(4-{3-[2-(1-adamantyl)-2-hydroxyethoxy]-1H-pyrazol-5-yl}phenyl)cyclohexyl]acetic acid | ABBOTT LABORATORIES (US) | 2012-06-19 | — | — | US | disclosed |
| EP-2117526-A2 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | Abbott Laboratories (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080182861-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBVIE INC. | 2008-07-31 | — | — | US | disclosed |
| WO-2008067257-A2 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238581-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | DGAT1, DGAT2, LCAT | DGAT1 1/4885NPSR1 3371/4885L3MBTL1 2297/4885 |
| US-20080182861-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | DGAT1, DGAT2, LCAT | DGAT1 1/4885NPSR1 3388/4885L3MBTL1 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.